REFERENCES

1. Larsen PR, Ingbar SH. 1992: The thyroid gland. In Williams Textbook of Endocrinology, 8th ed. Philadelphia, PA: WB Saunders Co ;p 357-487.

2. Polikar R, Burger AG, Scherer U, Nicod P. 1993:The thyroid and the heart. Circulation.; 87 (5)p 1435-1441

3. AACE Thyroid Task Force**;** 2002, AACE Clinical Practice Guidelines for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism;Endocrinology Practice (8)No. 6 ;p 457.

4**.** W. Frank Peacock 2005; The evolving role of BNP in the diagnosis and treatment of CHF:a summary of the BNP consensus panel report ,Emergency Medicine Cardiac Research and Education Group International (1).

5.Brent GA, Larsen PR 1996,Treatment of Hypothyroidism.:The Thyroid,(884).

6.Stephen Nussey and Saffron Whitehead 2001 'The Thyroid gland 'in Endocrinology: BIOS Scientific Publishers Ltd. ISBN 1-85996-252-1.

7. Krum et al 2001, Modified World Health Organization criteria for assessment of possible chronic heart failure.

8.Klein I. and Ojamaa K 2001,Thyroid hormone and the cardiovascular system. New England Journal of Medicine. 344(7) p. 501-509.

9.Kaisch H,Neumann T,Erbel Raimund 2007 ’Less increase of BNP and NT proBNP levels in obese patients with decompensated heart failure’International journal of cardiology ,1(133)p 22-24.

10**.**Mehra MR,Uber PA,Park M et al. 2004:Obesity and suppressed B-type natriuretic peptide levels in heart failure.JACC;43(9)p1590-1595

11**.**Klein I and Ojamaa K 2001 Thyroid Hormone and the Cardiovascular System,New England Journal of Medicine; 344 ;p 501-509.

12. Alex Harrison et al. 2002:B-type natriuretic peptide(BNP) predicts future cardiac events in patients representing to the emergency department with dyspnea ,.Annal of Emergency Medicine 39;p131-138.

13. Jansen J, Friesema ECH, Milici C, Visser TJ 2005. Thyroid hormone transporters in health and disease.Thyroid (15) ,p757-768.

14. Alireza M Manuchehri AM et al 2005 Thyroid dysfunction alters NT pro BNP concentrations, Department of Diabetics & Endocrinology, UK ,Endocrine Abstracts 9;p177.

15.KrauserDG ,Lioyd-Jones DM,Chae CU,Cameron R,Anwaruddin S,Baggish AL,Chen A,Tung R,Januzzi JL Jr, 2005. 'Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure' a ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) substudy.American Heart Journal.;149(4):p744-750.

16**.** Arikan S et al ,2007' Serum n-terminal pro –b-type natriuretic peptide(NT-proBNP) levels in patients with hyper and hypothyroidism. Hyperthyroidism may affect NT–proBNP levels as independent of cardiac dysfunction'European Congress of endocrinology ,(14) p 299.

17. Bluestein B,Belenky A , 2008 'NT-pro BNP:improved standard in CHF diagnosis 'Lab management' ;p 20-24.

18.Guber HA et al 2008;Evaluation of endocrine function, Henry's clinical diagnosis and management by laboratory methods,Elsevier;21st edition,p 333-338.

19. Collinson P.O, Barnes S. C. et al 2004 'Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers' European Journal of Heart Failure, 6 (3),p 365-368.

20**.**Goode KM et al, 2008 "Ruling out heart failure in primary-care: The cost-benefit of pre-screening using NT-proBNP and QRS width. International Journal of Cardiology.

21.Bay M et al 2003, NT-pro BNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function, Heart.; 89 (2) p 150–154.

22.Bastemin Mebmet 2007, Obesity is associated with increased serum TSH level ,independent of thyroid function, Swiss Med Weekly(137) p 431-434,.

23.Rivera Miguel et al 1999, 0bese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology,European journal of heart failure (7),p1168-1171.

24. Rodondi N, 2005, Nov 28:Sub clinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Archives of Internal Medicine;165(21):p 2460-2466.

25.Apple SF,Jaffe AS:Cardiac function ,In Burtis C A ,Ashwood E R,Bruns D E(eds) 2006:Tietz text book of clinical chemistry and molecular diagnostics:fourth edition,Elsevier,p1622-1670.

26..Anand IS,Fischer LD,Chiang YT,Latini R,Masson S,Maggioni AP,et al 2003;Changes in brain natriuretic peptide and norepineprine over time and mortality and morbidity in the Valsartan Heart Failure Trial.Circulation (107) p1278-83.

27.Hermann -Arnof KM ,Hanusch-Enserver U et al 2005, N-terminal Pro B- Type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals :Comparison with patients in different stages of Heart failure.clinical chemistry(51) p 844-848.

28.Wang TJ,Larson MG,Levy D,Benjamin EJ et al 2004;.Plasma natriuretic peptide levels and the risk of cardiovascular events and death.New England Journal of Medicine (350), p 655-63.

29.Mundy BJ,Mccord J,Nowak RM .2003;B natriuretic peptide levels and inversely related to body mass inden in patients with heart failure.Journal of American College of Cardologists (41) 58A.

30.Hanusch-Enserer U,Hermann KM,et al 2003; Effect of gastric binding on amino terminal pro brain natriuretic peptide in the morbidity obese. Obesity Research (11) p 695-698.

31.Rivera Miguel et al 2005,Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology , European journal of Heart Failure (7) p 1168-1170

32.R. Pfister, M. Scholzb, K. Wielckensb, E. Erdmanna, C.A. Schneide 2004 , Use of NT-proBNP in routine testing and comparison to BNP; European Journal of Heart Failure(6) p 289-293

33.Nielsen O. W, McDonagh, T. A. et al 2003. 'Retrospective analysis of the costeffectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population', Journal of American College of Cardiology, 41 (1) p 113-120.

34.McDonagh T. A., Holmer, S. et al 2004. 'NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies', European Journal Heart Failure, 6 (3) p 269-273.

35.Australia and Newzealand Horizon scanning network 2004,Elecsys® ProBNP Immunoassay for the Diagnosis of Congestive Heart Failure, (4).

36.Bayes-Genis A., Santalo-Bel, M. et al 2004. 'N-terminal probrain natriuretic

peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of

patients with dyspnoea and ventricular dysfunction' European Journal Heart Failure, 6 (3) p 301-308.

37. Wang F et al 2012; Relationship between thyroid function and ICU mortality: a prospective observation study, Critical Care , 16:R11

38.Scanlon M F,TOFT A.D 1996 ;Regulation of thyrotropin secretion;The Thyroid.7th ed.Philadelphia; p 220-240.

39.Hobbs, F. D., Davis, R. C. et al 2002. 'Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations', British Medical Journal 324 (7352), p1498.